Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Name: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
License: Public Domain

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

melanoma non

melanoma - currently enrolling, non-small cell lung cancer - enrollment completed, sarcoma - enrollment completed

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 287531
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.